Equillium Acquisition of Metacrine 2022

Equillium presents the acquisition of Metacrine, Inc., announced September 7, 2022. The combined company will advance itolizumab for autoimmune graft-versus-host disease and lupus nephritis, alongside EQ101 and EQ102 pipeline candidates. The merger integrates Equillium and Metacrine's clinical development capabilities and product platforms.